首页良性前列腺增生治疗及预后证据详情

Is Tamsulosin 0.2 mg Effective and Safe as a First-Line Treatment Compared with Other Alpha Blockers?: A Meta-Analysis and a Moderator Focused Study

原文:2016年 发布于 Yonsei Med J 57卷 第2期 407-18 浏览量:710次 原文链接

作者: Shim S. R. Kim J. H. Chang I. H. Shin I. S. Hwang S. D. Kim K. H. Yoon S. J. Song Y. S.

作者单位: Institute for Clinical Molecular Biology Research, Soonchunhyang University Hospital, Soonchunhyang University College of Medicine, Seoul, Korea. Department of Urology, Soonchunhyang University College of Medicine, Seoul, Korea. piacekjh@hanmail.net. Department of Urology, Chung-Ang University Hospital, Urological Science Institute, Chung-Ang University College of Medicine, Seoul, Korea. Department of Education, College of Education, Jeonju University, Jeonju, Korea. Department of Social Welfare, Kyungpook National University College of Social Science, Daegu, Korea. Department of Urology, Gil Hospital, Gachon University College of Medicine, Incheon, Korea. Department of Urology, Soonchunhyang University College of Medicine, Seoul, Korea.

归属分类: 良性前列腺增生治疗及预后证据

DOI: 10.3349/ymj.2016.57.2.407

关键词: Adrenergic alpha-1 Receptor Antagonists/*administration & dosage Adrenergic alpha-Antagonists Dose-Response Relationship Drug Humans Male Middle Aged Prostatic Hyperplasia *Quality of Life Sulfonamides/*administration & dosage Tamsulosin Prostatic hyperplasia alpha blockers

文献简介

PURPOSE: Tamsulosin 0.2 mg is used widely in Asian people, but the low dose has been studied less than tamsulosin 0.4 mg or other alpha blockers of standard dose. This study investigated the efficacy and safety of tamsulosin 0.2 mg by a meta-analysis and meta-regression. MATERIALS AND METHODS: We conducted a meta-analysis of efficacy of tamsulosin 0.2 mg using International Prostate Symptom Score (IPSS), maximal urinary flow rate (Qmax), post-voided residual volume (PVR), and quality of life (QoL). Safety was analyzed using adverse events. Relevant studies were searched using MEDLINE, EMBASE, and Cochrane library from January 1980 to June 2013. RESULTS: Ten studies were included with a total sample size of 1418 subjects [722 tamsulosin 0.2 mg group and 696 other alpha-blockers (terazosin, doxazosin, naftopidil, silodosin) group]. Study duration ranged from 4 to 24 weeks. The pooled overall standardized mean differences (SMD) in the mean change of IPSS from baseline for the tamsulosin group versus the control group was 0.02 [95% confidence interval (CI); -0.20, 0.25]. The pooled overall SMD in the mean change of QoL from baseline for the tamsulosin group versus the control group was 0.16 (95% CI; -0.16, 0.48). The regression analysis with the continuous variables (number of patients, study duration) revealed no significance in all outcomes as IPSS, QoL, and Qmax. CONCLUSION: This study clarifies that tamsulosin 0.2 mg has similar efficacy and fewer adverse events compared with other alpha-blockers as an initial treatment strategy for men with lower urinary tract symptoms.

热门文献